Skip To Main Content

Facts and Figures

Rankings

Biomedical engineering at Texas A&M University has been a degree-granting program since 1972 and has been ABET-accredited since 1977. The department's graduate program is ranked 17th among public institutions by U.S. News & World Report.
$24.8M research expenditures By U.S. News and World Report | American Society for Engineering Education

FY2023

29 faculty researchers Faculty directory

Faculty researchers on staff from 2022-2023

Student Enrollment

Enrollment (Fall 2024)
Student Level Number of Students
Undergraduate 496
Master's 63
Doctoral 119
Total Enrollment 678

Source: Office of Academic & Business Performance Analytics, Texas A&M University
As reported to the Texas Higher Education Coordinating Board.

Degrees Awarded

Degrees Awarded (Fall 2023, Spring 2024, Summer 2024)
Student Level Number of Students
Bachelor's 151
Master's 41
Doctoral 14
Total Degrees Awarded 206
Source: Office of Academic & Business Performance Analytics, Texas A&M University

Faculty

Our faculty members are involved in research from the macroscopic to the nanoscale in the areas of diagnostic and therapeutic systems, imaging systems, soft and hard tissue biomechanics, tissue characterizations, biomaterials used in the human body, orthopedic biomechanics, FDA regulatory practices, bioinstrumentation, measurement and analysis of human body signals, and analysis of the interaction between humans and medical devices. In addition, they have strong collaborations with medical and veterinary schools as well as various other departments throughout the university and around the world. 

Faculty (Fall 2023)
Tenure Status Number of Faculty
Tenured/Tenure-Track 29
Academic Professional Track 15
Total Faculty 44

Faculty Recognition

  • Eight Endowed Professorships
  • 29 editorships and editorial board memberships
  • 42 Fellow grades in professional societies
Our research has resulted in new patents, new companies and new economic activity. With increasing demands for quality medical devices, procedures and improved cost-effectiveness, we are positioned to lead the way in the development, testing and commercialization of products, systems and technologies.
  • $19M in external research funding (FY2021)
  • 65 patents filed
  • 38 disclosures filed
  • 11 start-up companies created, including one exit through acquisition by Medtronic, Inc.
  • 12 Invention Disclosures submitted and 20 Patents issued (US and non-US combined)

Research Areas